AURKB and chronic myelogenous leukemia, BCR-ABL1 positive: In the present study, AURKA and AURKB were pharmacologically targeted by reversine, a purine analogue that presents antineoplasic effects on multiple models of cancer26, including acute myeloid leukemia (AML)27, multiple myeloma16, and chronic myeloid leukemia (CML)21.